SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000947871-16-000965
Filing Date
2016-02-12
Accepted
2016-02-12 16:52:07
Documents
2
Group Members
DOMINIQUE SEMONMERLIN NEXUS IV, L.P.

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 3 ss1399413_sc13ga.htm SC 13G/A 110406
2 JOINT FILING AGREEMENT ss1399413_ex99b.htm EX-99.B 10599
  Complete submission text file 0000947871-16-000965.txt   122476
Mailing Address 230 PARK AVE, SUITE 928 NEW YORK NY 10169
Business Address 230 PARK AVE, SUITE 928 NEW YORK NY 10169 646-227-5270
Merlin BioMed Private Equity Advisors, L.L.C. (Filed by) CIK: 0001429303 (see all company filings)

IRS No.: 000000000
Type: SC 13G/A

Mailing Address 96 SKYWAY AVENUE TORONTO A6 M9W 4Y9
Business Address 96 SKYWAY AVENUE TORONTO A6 M9W 4Y9 (416) 595-0627
Trillium Therapeutics Inc. (Subject) CIK: 0001616212 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A6 | Fiscal Year End: 1214
Type: SC 13G/A | Act: 34 | File No.: 005-88719 | Film No.: 161420292
SIC: 2834 Pharmaceutical Preparations